MedTrace Logo

Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)

NCT00885690 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2013-09-04

No results posted yet for this study

Summary

Cognition is one of the core symptoms of schizophrenia. This study is a head-to-head trial between olanzapine and sertindole with cognition as primary outcome. The design is a 12-week double-blinded randomized controlled flexible dose study.

Conditions

Interventions

DRUG

Sertindole

Sertindole 16-24 mg once daily

DRUG

Olanzapine

Olanzapine 10-20 mg

Sponsors & Collaborators

  • Aalborg Psychiatric Hospital

    collaborator OTHER

  • Malmö University

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • René Nielsen, M.D. · Aalborg Psychiatric Hospital, Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00885690 on ClinicalTrials.gov